Type 1 diabetes mellitus
Diamyd Medical AB focuses its clinical research on Type 1 diabetes, with studies centered on preserving beta cell function and supporting glycemic control in people with recent diagnosis or elevated disease risk.
- Recent-onset Type 1 diabetes
- Preservation of insulin production
- Beta cell function
- Glycemic control
The sponsor’s work includes adolescents and adults with HLA DR3-DQ2 and GAD65 antibodies, reflecting a strong interest in immune-defined subgroups within autoimmune diabetes.
Autoimmune risk and early disease stages
Another key area is intervention in individuals at increased risk for Type 1 diabetes, including children and adolescents in Stage 1 and Stage 2 disease with multiple islet autoantibodies.
- Stage 1 Type 1 diabetes
- Stage 2 Type 1 diabetes
- Multiple islet autoantibodies
- Genetic susceptibility markers
These studies reflect interest in early immune-mediated diabetes before full clinical onset, with attention to genetically defined populations carrying the DR3-DQ2 haplotype.
Immune-targeted diabetes therapy
Diamyd Medical AB is engaged in research on antigen-specific immunotherapy for autoimmune diabetes, with a therapeutic focus on modulating the immune response linked to GAD65.
- GAD65-related autoimmunity
- Immune modulation
- Autoimmune diabetes
- Antigen-specific treatment
The clinical program spans both disease preservation in newly diagnosed patients and prevention-oriented studies in individuals at heightened genetic and immunologic risk.
Pediatric and adolescent endocrinology
The sponsor also has a clear interest in pediatric and adolescent endocrinology, particularly in children and teenagers with inherited susceptibility to Type 1 diabetes.
- Children at risk of Type 1 diabetes
- Adolescent diabetes care
- Early autoimmune screening
- Insulin-secreting cell preservation
Research activity extends across multiple sites in several countries, supporting clinical investigation in age groups where early immune intervention may be especially relevant.
